Pitavastatin (magnesium)

Pitavastatin magnesium is an orally active HMG-CoA Reductase inhibitor. Pitavastatin magnesium lowers total cholesterol and low-density lipoprotein cholesterol in a hyperlipidemic rat model. Pitavastatin magnesium can be used in research on cardiovascular and cerebrovascular diseases such as hyperlipidemia[1][2].

Product Specifications

CAS Number

[956116-90-8]

UNSPSC

12352100

Hazard Statement

H302-H312-H332

Target

HMG-CoA Reductase (HMGCR)

Related Pathways

Metabolic Enzyme/Protease

Applications

Neuroscience-Neuromodulation

Field of Research

Cardiovascular Disease

Smiles

[O-]C(CC1O[Mg+2](OC(CC2=O)CC(O)/C=C/C3=C(C4=CC=C(F)C=C4)C5=C(C=CC=C5)N=C3C6CC6)([O-]2)OC(C1)/C=C/C7=C(C8=CC=C(F)C=C8)C9=C(C=CC=C9)N=C7C%10CC%10)=O

Molecular Formula

C50H43F2MgN2O8

Molecular Weight

862.19

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P330-P363-P501

References & Citations

[1]Pitavastatin magnesium (Zypitamag) for hyperlipidemia. Med Lett Drugs Ther. 2018 Jun 18;60 (1549) :106. |[2]Abolhasani S, et al. Pitavastatin-induced cholesterol deficiency elevates serum biomarkers associated with statin-related adverse effects in rats. Cardiovasc Endocrinol Metab. 2025 Mar 7;14 (2) :e00326.